import ArticleLayout from "@/components/ArticleLayout";

const RetatrutideReview = () => (
  <ArticleLayout
    category="Deep Dive"
    title="Retatrutide: Why the Triple-Agonist Is Turning Heads"
    readTime="7 min read"
    date="February 2026"
    slug="retatrutide-triple-agonist-review"
    description="A straightforward look at Retatrutide, the first triple-agonist GLP-1, and why researchers think it could outperform semaglutide and tirzepatide."
  >
    <p>If you've been following the GLP-1 space at all, you already know the names: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). They've dominated headlines for years. But there's a newer compound generating serious buzz: <strong>Retatrutide</strong>. And it works differently to both of them.</p>

    <h2>Quick Recap: How GLP-1s Work</h2>
    <p>GLP-1 (glucagon-like peptide-1) is a gut hormone your body naturally produces after eating. It tells your brain you're full, slows digestion, and helps regulate blood sugar. GLP-1 agonist peptides mimic this effect, but last much longer than the natural hormone.</p>
    <p>That's the basic idea behind all three compounds. Where they differ is <em>how many receptors they hit</em>.</p>

    <h2>Semaglutide: The Single Agonist</h2>
    <p>Semaglutide targets one receptor: <strong>GLP-1</strong>. It's effective, well-studied, and has been through extensive Phase III trials. Weekly dosing typically ranges from 0.25mg up to 2.4mg.</p>
    <p>It works. But it only pulls one lever.</p>

    <h2>Tirzepatide: The Dual Agonist</h2>
    <p>Tirzepatide added a second target: <strong>GIP</strong> (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone that enhances insulin response and may improve fat metabolism. In the SURMOUNT trials, tirzepatide showed up to 22.5% body weight reduction, outperforming semaglutide in head-to-head comparisons.</p>
    <p>Two levers pulled. Better results. Logical enough.</p>

    <h2>Retatrutide: The Triple Agonist</h2>
    <p>Retatrutide goes further. It targets <strong>three receptors simultaneously</strong>:</p>
    <ul>
      <li><strong>GLP-1:</strong> appetite suppression and blood sugar regulation</li>
      <li><strong>GIP:</strong> enhanced insulin response and fat metabolism</li>
      <li><strong>Glucagon:</strong> increased energy expenditure and fat oxidation</li>
    </ul>
    <p>That third receptor is what makes Retatrutide genuinely different. Glucagon receptor activation promotes the body to burn stored fat for energy, essentially adding a thermogenic component that the other two compounds lack.</p>

    <h2>What the Data Shows</h2>
    <p>In Phase II trial data (published in the <em>New England Journal of Medicine</em>, 2023), participants on the highest dose of Retatrutide achieved an average weight loss of <strong>24.2% over 48 weeks</strong>. For context:</p>
    <ul>
      <li>Semaglutide 2.4mg: ~15-17% in comparable trials</li>
      <li>Tirzepatide 15mg: ~20-22.5% in SURMOUNT trials</li>
      <li>Retatrutide 12mg: ~24.2% in Phase II</li>
    </ul>
    <p>These are Phase II numbers. Phase III trials are ongoing and will provide more definitive data. But the early results are hard to ignore.</p>

    <h2>Side Effect Profile</h2>
    <p>The side effects are broadly similar across all three GLP-1 compounds, mostly GI-related:</p>
    <ul>
      <li>Nausea (especially during dose escalation)</li>
      <li>Reduced appetite (this is also the intended effect)</li>
      <li>Occasional diarrhoea or constipation</li>
      <li>Administration site reactions</li>
    </ul>
    <p>Some researchers on X have noted that Retatrutide's glucagon component may cause slightly more nausea in the titration phase, though this tends to settle. As @PeterAttiaMD has discussed, slow dose escalation remains the most practical way to manage these effects across all GLP-1 agonists.</p>

    <h2>Why People Are Excited</h2>
    <p>The peptide research community, particularly on X, has latched onto Retatrutide for a few reasons:</p>
    <ul>
      <li><strong>Best-in-class efficacy data,</strong> even from early trials</li>
      <li><strong>Novel mechanism:</strong> the glucagon component is genuinely new territory</li>
      <li><strong>Potential beyond weight loss:</strong> early signals for liver fat reduction (MASLD/NASH) are promising</li>
      <li><strong>Once-weekly dosing:</strong> same convenience as semaglutide and tirzepatide</li>
    </ul>

    <h2>The Bottom Line</h2>
    <p>Retatrutide isn't just another GLP-1. It's the first compound to activate three metabolic receptors at once, and the early data suggests this approach genuinely outperforms the current leaders. Phase III results will be decisive, but for researchers tracking the GLP-1 space, Retatrutide is the compound to watch.</p>
    <p>Whether it lives up to the hype will depend on the larger trial data, but on paper, the triple-agonist approach makes a compelling case.</p>
  </ArticleLayout>
);

export default RetatrutideReview;
